After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Ocular Therapeutix Inc is $1.32B. A total of 0.58 million shares were traded on the day, compared to an average of 1.63M shares.
In the most recent transaction, Nayak Sanjay sold 1,832 shares of OCUL for 9.02 per share on Aug 23 ’24. After the transaction, the Chief Strategy Officer now owns 176,194 company shares. In a previous transaction on Aug 23 ’24, Dugel Pravin sold 20,880 shares at 9.02 per share. OCUL shares that the insider owns now total 812,473.
Among the insiders who bought shares, RABIA OZDEN acquired of 18,333 shares on Aug 27 ’24 at a per-share price of $9.00. In another insider transaction, PRAVIN DUGEL bought 20,880 shares at $9.02 per share on Aug 23 ’24.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, OCUL has a high of $11.31 and a low of $2.00.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. OCUL’s latest balance sheet shows that the firm has $164.16M in Cash & Short Term Investments as of fiscal 2021. There were $58.98M in debt and $26.34M in liabilities at the time. Its Book Value Per Share was $2.43, while its Total Shareholder’s Equity was $88.00M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for OCUL is Buy with a score of 5.00.
